Celecoxib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Inclusion Criteria: * Histologically confirmed non-small cell lung cancer * Stage IIIB or IV disease * Radiographically measurable disease * 18 and over * Performance status: ECOG 0-2 * Renal: Creatinine ≤ 2 mg/dL * Negative pregnancy test * Fertile patients must use effective contraception * More than 4 weeks since prior chemotherapy * Endocrine therapy: More than 4 weeks since prior corticosteroids; No concurrent corticosteroids, including chronic corticosteroids, except for medically-indicated topical steroids * Radiotherapy: More than 4 weeks since prior radiotherapy * More than 4 weeks since other prior anticancer therapy * More than 4 weeks since prior non-cytotoxic investigational agents * At least 72 hours since prior nonsteroidal anti-inflammatory drugs (NSAIDs) Exclusion Criteria: * pregnant or nursing * comorbid disease, psychiatric condition, chronic medical condition, or laboratory abnormality that would preclude study treatment or compliance with study requirements * hypersensitivity to celecoxib, sulfonamides, aspirin, other NSAIDs, or any study reagent * history of gastrointestinal ulceration, bleeding, or perforation * other concurrent cyclooxygenase-2 or -3 inhibitors * other concurrent NSAIDs